Take­da winds down Ther­a­vance pact, culls part­nered Crohn's pro­gram af­ter PhII flops

Take­da re­vealed in its lat­est quar­ter fil­ing that it’s end­ing a sev­en-year al­liance with Ther­a­vance as the com­pa­nies fold a pro­gram that flopped in Phase IIb, while al­so giv­ing the axe to a sec­ond part­ner­ship with France’s En­terome in Crohn’s. These pro­grams were among sev­en tri­als Take­da is cut­ting for var­i­ous can­cers and oth­er dis­eases amidst a plan to lay off more than 180 work­ers.

TAK-954, a can­di­date be­ing de­vel­oped in Phase II tri­als for pa­tients be­fore surgery to see if it could en­hance the re­cov­ery of gas­troin­testi­nal func­tion af­ter surgery to re­sec­tion the small or large in­tes­tine, was al­so cut. Some pa­tients al­so got the drug post-surgery to see if it helped at all in the tri­al. Take­da not­ed in its quar­ter­ly re­port that the Phase IIb study for TAK-954 did not meet its end­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER